Prana Biotechnology (PRAN)

[Kadaicher1]

Hi RKF, the trial has identified plaque reduction. A statement they made on page 3 of the report was interesting, indicating no changes in measurements between 1yr and 2 yr.
http://pranabio.com/wp-content/uploads/2015/08/150826_Prana-Annual-Report-and-4E.pdf
That would be brilliant if the patients were more advanced, but the differences over one year in these earlier stage patients would possibly have been tiny. I would take from that data that PBT2 may have stopped or slowed AD in the second year but the trial is too small to be able to reach that conclusion. Still, no changes over one year is a good sign.
When Prana started the Reach2HD and IMAGINE trials it was always the plan that Reach2HD would lead PBT2 to market and IMAGINE was run to try to attract a pharma partner for the AD program with a demonstration of target engagement.
They are still on track with HD for phase3, and like you I don't think they will have a problem getting the partial hold lifted when the safety analysis and HD trial design are complete.